Company: CERO
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001213900-25-079898
Chunk: 166

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 166
---
Series C Convertible Preferred Stock

The
Company designated 2,853 shares of its authorized preferred stock as the Series C Preferred Stock and the rights, preferences and privileges
of the Series C Preferred Stock are summarized below.

Each
share of Series C Preferred Stock has a stated value of $1,000 per share and, when issued, the Series C Preferred Stock was fully paid
and non-assessable. The Series C Preferred Stock, ranks senior to all other Company capital stock unless required holder votes are obtained
to create a class of stock senior to Series C Preferred Stock.

Ranking:
The Series C Preferred Stock are senior in rank with respect to the preferences as to dividends, distributions and payments upon the
liquidation, dissolution and winding up of the Company to the Series A Convertible Preferred Stock, the Series B Convertible Preferred
Stock, and Common Stock. The Company shall not, without the consent of the Required Holders, authorize or issue any shares of senior
rank with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution and winding up of
the Company, shares of pari passu rank with respect to the preferences as to dividends, distributions and payments upon the liquidation,
dissolution and winding up of the Company, or shares of junior ranking stock that have a maturity or redemption date prior to the first
anniversary of the Series C Preferred Stock issuance date.

Dividend
and Participation Rights: The holders of Series C Preferred Stock will be entitled to dividends, on an as-if converted basis, equal
to and in the same form as dividends actually paid on shares of Common Stock, when and if actually paid. Series C Preferred Stockholders
will be entitled to participate pro rata in any purchase rights extended to holders of Common Stock on an as-converted basis.

Conversion:
Each holder of Series C Preferred Stock may convert at any time, all, or any part, of the outstanding Series C Preferred Stock into shares
of the Common Stock at the initial “Conversion Price” of $448.00, which is subject to customary adjustments for stock splits.

Alternate
Conversion: Following the occurrence and during the continuance of a Trigger Event (as defined below), each holder may alternatively
elect to convert the Series C Preferred Stock at the “Alternate Conversion Price” equal to the lesser of the then current
Conversion Price and the greater of $39.20 (the “Series C Conversion Price Floor”) or 80% of the trailing 5-day daily volume
weighted average